Comparative Pharmacology
Head-to-head clinical analysis: BAMATE versus TRANMEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAMATE versus TRANMEP.
BAMATE vs TRANMEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of BAMATE is not well established; it is thought to involve inhibition of monoamine oxidase (MAO) with preferential inhibition of MAO-B at low doses, leading to increased concentrations of dopamine and other biogenic amines in the brain.
Tianeptine is a selective serotonin reuptake enhancer (SSRE) and also modulates glutamatergic signaling via AMPA and NMDA receptors. It increases serotonin transport in presynaptic neurons and enhances neuroplasticity.
400 mg orally twice daily
50 mg orally every 8 hours, may increase to 100 mg every 8 hours if needed.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults. This short half-life necessitates frequent dosing to maintain therapeutic levels.
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateMeprobamate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate."
Clinical Note
moderateMeprobamate + Haloperidol
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol."
Clinical Note
moderate4-6 hours in adults; prolonged in hepatic impairment (up to 12 hours) and elderly.
BAMATE is primarily excreted renally as unchanged drug (approximately 60-70%) and as glucuronide conjugates (20-30%). Fecal elimination accounts for less than 10%.
Renal: ~60% as unchanged drug, biliary/fecal: ~30% as metabolites, remainder as unchanged drug.
Category C
Category C
Anxiolytic
Anxiolytic
Felbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."